Charles River Laboratories International (CNSX:CRL) and Imagion Biosystems (ASX:IBX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.
Valuation and Earnings
This table compares Charles River Laboratories International and Imagion Biosystems' revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Charles River Laboratories International | N/A | N/A | N/A | N/A | N/A |
Imagion Biosystems | $2.70 million | 0.00 | $-7,253,610.11 | A($0.01) | N/A |
Charles River Laboratories International has higher earnings, but lower revenue than Imagion Biosystems.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Charles River Laboratories International and Imagion Biosystems, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Charles River Laboratories International | 0 | 0 | 0 | 0 | N/A |
Imagion Biosystems | 0 | 0 | 0 | 0 | N/A |
Profitability
This table compares Charles River Laboratories International and Imagion Biosystems' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Charles River Laboratories International | N/A | N/A | N/A |
Imagion Biosystems | N/A | N/A | N/A |
Summary
Imagion Biosystems beats Charles River Laboratories International on 1 of the 1 factors compared between the two stocks.